Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Trial sponsor
AstraZeneca
Scientific Title
A Phase 2, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd, DS-8201a) for the Treatment of Selected HER2 Expressing Tumors (DESTINY-PanTumor02)